| 曹彦1 易艳荣2.非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究[J].,2011,11(10):1817-1820 |
| 非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究 |
| Expression of SOCS-3 in the Liver of Rats with Nonalcoholic Fatty LiverDisease and Therapeutic Effects of Pioglitazone |
| |
| DOI： |
| 中文关键词: 非酒精性脂肪肝病 SOCS-3 吡格列酮 |
| 英文关键词: Nonalcoholic fatty liver SOCS-3 Pioglitazone |
| 基金项目: |
|
| 摘要点击次数: 572 |
| 全文下载次数: 821 |
| 中文摘要: |
| 目的：探讨SOCS-3 在非酒精性脂肪肝病（NAFLD）发病中的作用以及吡格列酮的干预作用。方法：29 只雄性SD 大鼠随机分
为正常对照组（8 只），高脂饮食组（21 只）。饲养8 周后，从高质饮食组随机抽取5 只大鼠证实造模成功后，将该组余下的16 只大
鼠继续以高脂饲料喂养，并随机分为NAFLD 对照组（8 只）；吡格列酮干预组（8 只），予以吡格列酮3mg·kg-1·d-1 灌胃。16 周末，处
死所有大鼠，检测血糖、血胰岛素、血脂、肝脏SOC S-3mRNA 和SREBP-1c mRNA 表达及肝脏病理学。结果：与正常对照组相比，
NAFLD 组血糖、血胰岛素、血脂、肝脏脂肪变水平及肝组织SOCS-3mRNA、SREBP1c mRNA 表达显著上调。吡格列酮干预组
SOCS-3mRNA、SREBP-1cmRNA 表达较NAFLD 组下调，且血糖、血胰岛素、血脂、肝脏脂肪变水平下降。SOCS-3mRNA 表达水平
与胰岛素抵抗指数、SREBP-1c mRNA 表达水平、肝脂肪变成显著正相关。结论：SOCS-3 可能通过胰岛素抵抗及上调肝组织
SREBP-1c mRNA 表达参与NAFLD 发病，吡格列酮能抑制肝脏SOCS-3 的表达，对NAFLD 有一定治疗作用。 |
| 英文摘要: |
| Objective: To investigate the role of suppressors of cytokine signaling protein(SOCS-3) in the pathogenesis of patients
with nonalcoholic fatty liver as well as the effects of pioglitazone. Methods: Twenty-nine male SD rats were randomized into normal
control group (n=8, fed with normal food), high fat diet group (n=21, fed with fat-rich food). Killed 5 rats of high fat diet group after 8
weeks, and confirmed that the model of NAFLD was successfully established. Then the remaining 16 rats were divided into 2 subgroups:
NAFLD control group (n=8, fed with continuously with fat-rich food), pioglitazone intervention group (n=8, fed with continuously with
fat-rich food and pioglitazone 3 mg·kg-1·d-1 by gastric perfusion). By the end of 16th week , all rats were killed to isolate the serum to test
the levels of FBG, FINS, TG and TC. The SOCS-3 mRNA and SREBP-1c mRNA expression of rat liver were analyzed by RT-PCR.
Results: Compared with control group, the serum levels of FBG, FINS, TC, TG and the liver SOCS-3 and SREBP-1c expression levels,
liver fatty degeneration grades of NAFLD group were all up-regulated (P<0.05). The serum levels of FBG, FINS, TC, TG of pioglitazone
intervention group were significantly lower than NAFLD control group (P<0.05); the liver SOCS-3 and SREBP-1c expression levels of
pioglitazone intervention group were also lower than NAFLD control group(P<0.05). Meanwhile, the fatty degeneration grades of liver of
pioglitazone intervention group was lower than NAFLD control group (P<0.05). The liver SOCS-3 mRNA expression levels positively
correlated with HOMA-IR, the liver SREBP-1c mRNA expression levels and the fatty degeneration grades(P<0.05). Conclusion: SOCS-3
might be involved in nonalcoholic fatty liver through insulin resistance and up-regulating SREBP-1c mRNA expression, and pioglitazone
therapy could decrease the SOCS-3mRNA expression and effectively treat nonalcoholic fatty liver. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
